Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir

C. Ippoliti, A. Morgan, D. Warkentin, K. Van Besien, R. Mehra, I. Khouri, S. Giralt, J. Gajewski, R. Champlin, B. Andersson, D. Przepiorka

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Cytomegalovirus (CMV) disease can be prevented by administration of ganciclovir prophylactically post-transplant. However, up to 30% of patients discontinue use of ganciclovir as a result of profound neutropenia and may subsequently develop CMV infections while unprotected. To prevent reactivation of CMV, we administered foscarnet to 39 adults unable to receive ganciclovir due to delayed engraftment or ganciclovir-induced neutropenia. Twenty-four (62%) of the patients had received T cell-depleted marrow transplants. Foscarnet sodium 60 mg/kg i.v. daily was continued until the neutropenia resolved, at which time ganciclovir was resumed. CMV prophylaxis commenced at a median of 28 days following transplantation. Median time to initiation of foscarnet was day 60 post-transplant, and the median duration of treatment was 22 days. Foscarnet was well-tolerated. Six (15%) patients had CMV detected while receiving prophylaxis, and CMV-related mortality was 5%. Foscarnet is a safe and effective agent for prevention of CMV disease in allogeneic transplant recipients unable to receive ganciclovir.

Original languageEnglish (US)
Pages (from-to)491-495
Number of pages5
JournalBone Marrow Transplantation
Volume20
Issue number6
StatePublished - Sep 2 1997
Externally publishedYes

Fingerprint

Foscarnet
Ganciclovir
Cytomegalovirus Infections
Cytomegalovirus
Bone Marrow
Neutropenia
Transplants
Transplant Recipients
Transplantation
T-Lymphocytes
Mortality

Keywords

  • Allogeneic
  • BMT
  • Cytomegalovirus
  • Foscarnet
  • Ganciclovir

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Ippoliti, C., Morgan, A., Warkentin, D., Van Besien, K., Mehra, R., Khouri, I., ... Przepiorka, D. (1997). Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir. Bone Marrow Transplantation, 20(6), 491-495.

Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir. / Ippoliti, C.; Morgan, A.; Warkentin, D.; Van Besien, K.; Mehra, R.; Khouri, I.; Giralt, S.; Gajewski, J.; Champlin, R.; Andersson, B.; Przepiorka, D.

In: Bone Marrow Transplantation, Vol. 20, No. 6, 02.09.1997, p. 491-495.

Research output: Contribution to journalArticle

Ippoliti, C, Morgan, A, Warkentin, D, Van Besien, K, Mehra, R, Khouri, I, Giralt, S, Gajewski, J, Champlin, R, Andersson, B & Przepiorka, D 1997, 'Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir', Bone Marrow Transplantation, vol. 20, no. 6, pp. 491-495.
Ippoliti C, Morgan A, Warkentin D, Van Besien K, Mehra R, Khouri I et al. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir. Bone Marrow Transplantation. 1997 Sep 2;20(6):491-495.
Ippoliti, C. ; Morgan, A. ; Warkentin, D. ; Van Besien, K. ; Mehra, R. ; Khouri, I. ; Giralt, S. ; Gajewski, J. ; Champlin, R. ; Andersson, B. ; Przepiorka, D. / Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir. In: Bone Marrow Transplantation. 1997 ; Vol. 20, No. 6. pp. 491-495.
@article{d3c9c79f09a2435d96a827ef7016e027,
title = "Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir",
abstract = "Cytomegalovirus (CMV) disease can be prevented by administration of ganciclovir prophylactically post-transplant. However, up to 30{\%} of patients discontinue use of ganciclovir as a result of profound neutropenia and may subsequently develop CMV infections while unprotected. To prevent reactivation of CMV, we administered foscarnet to 39 adults unable to receive ganciclovir due to delayed engraftment or ganciclovir-induced neutropenia. Twenty-four (62{\%}) of the patients had received T cell-depleted marrow transplants. Foscarnet sodium 60 mg/kg i.v. daily was continued until the neutropenia resolved, at which time ganciclovir was resumed. CMV prophylaxis commenced at a median of 28 days following transplantation. Median time to initiation of foscarnet was day 60 post-transplant, and the median duration of treatment was 22 days. Foscarnet was well-tolerated. Six (15{\%}) patients had CMV detected while receiving prophylaxis, and CMV-related mortality was 5{\%}. Foscarnet is a safe and effective agent for prevention of CMV disease in allogeneic transplant recipients unable to receive ganciclovir.",
keywords = "Allogeneic, BMT, Cytomegalovirus, Foscarnet, Ganciclovir",
author = "C. Ippoliti and A. Morgan and D. Warkentin and {Van Besien}, K. and R. Mehra and I. Khouri and S. Giralt and J. Gajewski and R. Champlin and B. Andersson and D. Przepiorka",
year = "1997",
month = "9",
day = "2",
language = "English (US)",
volume = "20",
pages = "491--495",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir

AU - Ippoliti, C.

AU - Morgan, A.

AU - Warkentin, D.

AU - Van Besien, K.

AU - Mehra, R.

AU - Khouri, I.

AU - Giralt, S.

AU - Gajewski, J.

AU - Champlin, R.

AU - Andersson, B.

AU - Przepiorka, D.

PY - 1997/9/2

Y1 - 1997/9/2

N2 - Cytomegalovirus (CMV) disease can be prevented by administration of ganciclovir prophylactically post-transplant. However, up to 30% of patients discontinue use of ganciclovir as a result of profound neutropenia and may subsequently develop CMV infections while unprotected. To prevent reactivation of CMV, we administered foscarnet to 39 adults unable to receive ganciclovir due to delayed engraftment or ganciclovir-induced neutropenia. Twenty-four (62%) of the patients had received T cell-depleted marrow transplants. Foscarnet sodium 60 mg/kg i.v. daily was continued until the neutropenia resolved, at which time ganciclovir was resumed. CMV prophylaxis commenced at a median of 28 days following transplantation. Median time to initiation of foscarnet was day 60 post-transplant, and the median duration of treatment was 22 days. Foscarnet was well-tolerated. Six (15%) patients had CMV detected while receiving prophylaxis, and CMV-related mortality was 5%. Foscarnet is a safe and effective agent for prevention of CMV disease in allogeneic transplant recipients unable to receive ganciclovir.

AB - Cytomegalovirus (CMV) disease can be prevented by administration of ganciclovir prophylactically post-transplant. However, up to 30% of patients discontinue use of ganciclovir as a result of profound neutropenia and may subsequently develop CMV infections while unprotected. To prevent reactivation of CMV, we administered foscarnet to 39 adults unable to receive ganciclovir due to delayed engraftment or ganciclovir-induced neutropenia. Twenty-four (62%) of the patients had received T cell-depleted marrow transplants. Foscarnet sodium 60 mg/kg i.v. daily was continued until the neutropenia resolved, at which time ganciclovir was resumed. CMV prophylaxis commenced at a median of 28 days following transplantation. Median time to initiation of foscarnet was day 60 post-transplant, and the median duration of treatment was 22 days. Foscarnet was well-tolerated. Six (15%) patients had CMV detected while receiving prophylaxis, and CMV-related mortality was 5%. Foscarnet is a safe and effective agent for prevention of CMV disease in allogeneic transplant recipients unable to receive ganciclovir.

KW - Allogeneic

KW - BMT

KW - Cytomegalovirus

KW - Foscarnet

KW - Ganciclovir

UR - http://www.scopus.com/inward/record.url?scp=0030805973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030805973&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 491

EP - 495

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 6

ER -